**Dr. Ingo V. Hartung**

Executive Director & Global Head of Medicinal Chemistry & Drug Design

Global Research & Development

Merck HealthCare KGaA

Darmstadt/Germany

**Biographical sketch:**

Ingo V. Hartung is a synthetic organic chemist by training (PhD University of Hannover/Germany, Postdoc Stanford University/US) with close to 20 years of Pharma industry experience (Schering AG, Bayer AG, Merck KGaA). He has been project leader in oncology and cardiology NCE drug discovery and has had portfolio responsibility for preclinical research in the areas of epigenetics and immuno-oncology. Ingo is heading Merck's Medicinal Chemistry & Drug Design department which is driving drug discovery projects in oncology & immunology covering various types of small molecule modalities. His research interests comprise all aspects of innovation in small molecule drug discovery with a special focus on novel modalities like protein degraders. Ingo Hartung is a member of the Scientific Advisory Board of ChemMedChem and on the Advisory Board of the President of the European Federation of Medicinal Chemistry. He is the author of >50 scientific publications and patents.

**Key publications:**

*A miniaturized mode-of-action profiling platform enables high throughput characterization of the molecular and cellular dynamics of EZH2 inhibition*. *Scientific reports* **2024**, article number 1739.

*Which Small Molecule? Selecting Chemical Probes for Use in Cancer Research and Target Validation. Cancer Discovery* **2023**, *23*, 1.

*Expanding Chemical Probe Space: Quality Criteria for Covalent and Degrader Probes*. *J. Med. Chem.* **2023**, *66*, 9297.

*New Generation of sGC Stimulators: Discovery of Imidazo[1,2-a]pyridine Carboxamide BAY 1165747 (BAY-747), a Long-Acting Soluble Guanylate Cyclase Stimulator for the Treatment of Resistant HypertensionPROxAb shuttle*. *J. Med. Chem.* **2023**, *66*, 7280.

*Rules were made to be broken*. *Nat. Rev. Chem.* **2023**, *7*, 3.

*Systematic Potency and Property Assessment of VHL Ligands and Implications on PROTAC Design*. *ChemMedChem* **2023**, *18*, e202200615.

*No shortcuts to SARS-CoV-2 antivirals*. *Science* **2021**, *373*, 488.

*Amine-Catalysed Suzuki–Miyaura-Type Coupling? the Identification and Isolation of the Palladium Culprits*. *Nat. Chem.* **2021.**

*Discovery and Characterization of a Highly Potent and Selective Aminopyrazoline-Based in Vivo Probe (BAY-598) for the Protein Lysine Methyltransferase SMYD2*. *J. Med. Chem.* **2016**, *59*, 4578.

*Modular Assembly of Allosteric MEK Inhibitor Structural Elements Unravels Potency and Feedback-Modulation Handles*. *ChemMedChem* **2015**, *10*, 1941.